ImmunityBio (NASDAQ:IBRX) Stock Price Down 9.2% – Here’s What Happened

Shares of ImmunityBio, Inc. (NASDAQ:IBRX) traded down 9.2% during trading on Thursday . The company traded as low as $7.45 and last traded at $7.3090. 6,173,525 shares traded hands during trading, a decline of 79% from the average session volume of 29,679,039 shares. The stock had previously closed at $8.05.

Key Stories Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: The FDA accepted ImmunityBio’s supplemental BLA for ANKTIVA plus BCG in BCG-unresponsive non-muscle invasive bladder cancer, setting a PDUFA date of January 6, 2027. This keeps a major growth catalyst alive and supports the recent move higher in the stock. Article Title
• Positive Sentiment: BTIG and HC Wainwright both reiterated buy ratings on ImmunityBio, with price targets of $12 and $15, suggesting analysts still see meaningful upside from current levels. Article Title
• Positive Sentiment: News that the FDA is reviewing ANKTIVA’s label expansion for bladder cancer has reinforced investor optimism around a potential broader approval path. Article Title
• Neutral Sentiment: Several law firms issued reminders about the May 26 lead-plaintiff deadline in the pending class-action lawsuit, which keeps the litigation in focus but does not add new allegations. Article Title
• Neutral Sentiment: Additional reports highlighted that ImmunityBio secured five U.S. patents for Anktiva in bladder cancer, which is supportive longer term but not as immediately market-moving as the FDA and legal developments. Article Title
• Negative Sentiment: The biggest headwind is the securities class action tied to the FDA’s warning letter, with multiple firms alleging investors were harmed by misleading efficacy claims; this legal risk is weighing on sentiment. Article Title

Wall Street Analyst Weigh In

A number of research firms recently weighed in on IBRX. BTIG Research restated a “buy” rating and set a $12.00 target price on shares of ImmunityBio in a research note on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ImmunityBio in a report on Tuesday, April 14th. Piper Sandler reaffirmed an “overweight” rating and issued a $12.00 target price (up from $7.00) on shares of ImmunityBio in a report on Wednesday, March 4th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of ImmunityBio in a report on Monday, February 23rd. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $23.00 target price on shares of ImmunityBio in a report on Tuesday, May 5th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $14.20.

ImmunityBio Stock Down 5.5%

The company has a market capitalization of $7.97 billion, a PE ratio of -8.96 and a beta of 0.02. The company’s 50 day moving average is $7.77 and its two-hundred day moving average is $5.53.

ImmunityBio (NASDAQ:IBRX) last posted its earnings results on Thursday, May 7th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.54). The company had revenue of $44.21 million for the quarter, compared to the consensus estimate of $43.07 million. Analysts forecast that ImmunityBio, Inc. will post -0.31 EPS for the current year.

Insider Buying and Selling at ImmunityBio

In related news, Director Barry J. Simon sold 165,000 shares of the firm’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $10.25, for a total transaction of $1,691,250.00. Following the completion of the transaction, the director directly owned 2,925,821 shares of the company’s stock, valued at approximately $29,989,665.25. This trade represents a 5.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Christobel Selecky sold 25,000 shares of the firm’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $10.00, for a total transaction of $250,000.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 275,000 shares of company stock valued at $2,934,500 over the last ninety days. 69.48% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On ImmunityBio

Institutional investors have recently bought and sold shares of the stock. Western Wealth Management LLC purchased a new position in ImmunityBio during the first quarter valued at $44,000. Geneos Wealth Management Inc. grew its stake in ImmunityBio by 579.3% during the first quarter. Geneos Wealth Management Inc. now owns 5,754 shares of the company’s stock valued at $44,000 after acquiring an additional 4,907 shares in the last quarter. Archer Investment Corp grew its stake in shares of ImmunityBio by 67.1% in the 1st quarter. Archer Investment Corp now owns 5,872 shares of the company’s stock worth $45,000 after buying an additional 2,358 shares in the last quarter. Hodges Capital Management Inc. purchased a new position in shares of ImmunityBio in the 1st quarter worth $77,000. Finally, Aaron Wealth Advisors LLC purchased a new stake in shares of ImmunityBio during the 1st quarter valued at about $78,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.